The Question Everyone Over 60 Is Asking
If you’re on hormone replacement therapy and approaching or past 60, you’ve probably heard some version of this: “You should stop HRT at 60” or “Five years is the maximum.” Maybe your primary care doctor suggested discontinuing. Maybe a friend told you it’s dangerous after a certain age. Maybe you read a headline from 2002.
The reality is more nuanced than any of these statements. And the evidence has changed dramatically since the initial WHI results that created widespread fear about HRT.
The answer to “Is HRT safe after 60?” depends on three specific variables:
- When did you start? — Continuing HRT you started at 52 is fundamentally different from starting HRT for the first time at 63.
- What type and route? — Transdermal estrogen-only therapy carries different risks than oral combined estrogen-progestogen.
- What’s your individual risk profile? — Cardiovascular health, breast cancer risk, bone density, and symptom severity all factor in.
Continuing HRT Past 60: The Evidence
If you initiated HRT within the “timing window” — within 10 years of menopause onset or before age 60 — and have been on therapy for several years without complications, the evidence supports considering continuation with annual reassessment.
The NAMS 2022 position statement is explicit: “Arbitrary limits should not be placed on the duration of hormone therapy.” The duration should be individualized based on whether symptoms persist, the impact on quality of life, and the patient’s evolving risk-benefit ratio.
This means there is no magic age at which HRT automatically becomes unsafe. A healthy 65-year-old who started transdermal estradiol at 52, has normal mammograms, no cardiovascular disease, and continues to benefit from symptom relief is in a very different situation than the blanket “stop at 60” recommendation suggests.
“For women aged older than 60 years or who are more than 10 years from menopause onset, the benefits and risks of initiating hormone therapy should be weighed on an individualized basis. For women who initiated hormone therapy within 10 years of menopause, continued use should be reevaluated periodically with shared decision-making.” NAMS 2022
Starting HRT After 60: A Different Calculus
Initiating systemic HRT for the first time after 60 is a different conversation. The WHI reanalysis Manson, JAMA 2013 showed that women who started HRT more than 10 years after menopause had a less favorable cardiovascular risk profile than early initiators. The protective effect on healthy arterial endothelium (the timing hypothesis) may not apply when atherosclerotic changes have already developed.
This does not mean it is always contraindicated. It means the decision requires more careful evaluation — including cardiovascular risk assessment, coronary artery calcium scoring in some cases, and a thorough discussion of alternatives. For some women with severe symptoms and low cardiovascular risk, carefully dosed transdermal estrogen may still be reasonable. For others, non-hormonal alternatives (fezolinetant, SSRIs, gabapentin) may be more appropriate.
There is one important exception: low-dose vaginal estrogen for genitourinary syndrome of menopause (vaginal dryness, painful intercourse, recurrent UTIs) can be safely started at any age. It has minimal systemic absorption, does not require concurrent progestogen in most cases, and can be continued indefinitely.
Do not start or stop HRT without medical guidance. Abruptly discontinuing HRT can cause severe rebound vasomotor symptoms in approximately 50% of women. If you and your physician decide to stop, gradual tapering over 3–6 months is recommended. And starting systemic HRT for the first time after 60 should only be done after comprehensive risk assessment by a physician experienced in menopause management.
The Breast Cancer Question
Breast cancer risk is the concern that weighs most heavily on HRT decisions after 60. The evidence is specific and worth understanding precisely:
- Combined E+P (estrogen + progestogen): Carries a small increased breast cancer risk after approximately 5 years of use — about 8 additional cases per 10,000 women per year WHI, JAMA 2002. For women who have been on E+P for many years, this risk is cumulative and is a key factor in annual reassessment.
- Estrogen-only therapy: In women without a uterus, the WHI estrogen-only arm showed no increase and a possible decrease in breast cancer risk Chlebowski, JAMA 2020. This is a significant distinction for post-hysterectomy women.
- Route matters: Transdermal estrogen does not carry the same venous thromboembolism risk as oral estrogen Canonico, BMJ 2008, making it the preferred route for older women on continued therapy.
The bottom line: the breast cancer risk is real for combined therapy, small in absolute terms, and must be weighed against the benefits of continued treatment. For estrogen-only therapy, this specific concern does not apply based on current evidence.
What Annual Reassessment Looks Like
At Broad Medical Group, every patient on HRT receives an annual reassessment that evaluates:
- Symptom status: Are vasomotor symptoms still present? Would they recur if HRT were stopped?
- Quality of life impact: How significantly does HRT contribute to sleep, mood, sexual function, and daily wellbeing?
- Cardiovascular risk: Blood pressure, lipid panel, any new cardiovascular events or risk factors.
- Breast cancer screening: Annual mammogram, any new findings, updated risk assessment.
- Bone density: DEXA scan status, ongoing bone protection needs.
- Medication review: Is the current dose still appropriate? Could a lower dose maintain benefits with reduced risk?
This is not a rubber stamp. It is a genuine reassessment of whether continuing therapy remains in the patient’s best interest. For a comprehensive overview of the HRT candidacy framework, monitoring protocols, and treatment options, see our Menopause & HRT Evidence-Based Guide.
- Continuing HRT past 60 is not automatically unsafe — for women who started within the timing window, NAMS 2022 supports individualized continuation without arbitrary age cutoffs.
- Starting HRT for the first time after 60 requires more caution — cardiovascular risk assessment is essential, and the risk-benefit ratio is less favorable than early initiation.
- Vaginal estrogen can be started at any age — minimal systemic absorption, no time limit, effective for genitourinary symptoms.
- Combined E+P carries a small breast cancer risk with long-term use — estrogen-only therapy does not (WHI data).
- Transdermal route is preferred for older women — no increased VTE risk compared to oral.
- Annual reassessment is non-negotiable — symptom status, cardiovascular risk, breast screening, and dose adequacy reviewed every year.
- Never stop abruptly — gradual taper over 3â€"6 months if discontinuing.